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Summary Flow cytometric (FCM) estimation of DNA content has been performed on tumour tissue from
197 patients with high and intermediate grade non-Hodgkin's lymphoma (NHL) to investigate the
clinicopathological correlations and prognostic significance of DNA ploidy and proliferative activity. Fifty-one
per cent of tumours were diploid; the remaining non-diploid tumours were near diploid (14%), aneuploid
(28%) and tetraploid (7%). In 81 tumours multiple analyses were performed from different regions of the
tumour, ploidy discrepancy was seen within the same tumour in 13/81 tumours (16%), and intra-tumour
variation in proliferative index (PI) in 72 tumours was estimated at ±5%. Ploidy status did not correlate with
histological subtype (Kiel or Rappaport), Ann Arbor stage or the site of disease at presentation. There was no
significant difference in response rate, relapse-free survival (RFS) or overall survival rate between the different
ploidy categories. Tumour proliferative index (PI) varied markedly between patients (range 2-51%, median
14%). A significant association was observed between PI and histological subtype in the Kiel classification
(P = 0.001). The median PI for the lymphoblastic lymphomas was 20% compared with 10% for the
centrocytic tumours. An elevated PI was significantly associated with a reduced response rate (P = 0.023), with
71% of patients with a low PI (<20%) achieving complete remission (CR) compared with 49% patients with
a high PI (>20%). Despite this correlation with CR, PI was not significantly associated with overall survival.
When the DNA data was combined with over 20 other potential prognostic factors in multivariate analysis,
ploidy and proliferative activity did not prove to be of independent prognostic significance for response, RFS
or overall survival. In 20 patients additional biopsy material was available from the site of subsequent relapse.
In these cases, although the histology at relapse remained unchanged, ploidy status altered in 13/20 patients,
and there was a significant rise in tumour PI at relapse compared with the initial pre treatment biopsy
(P = 0.017). We conclude that in high and intermediate grade NHL, DNA ploidy as assessed using conven-
tional FCM analysis is not significantly associated with clinical outcome. However, proliferative activity does
correlate with histological subtype and response to therapy, and this parameter warrants further evaluation in
future studies.
With the advent of intensive combination chemotherapy,
durable remissions have been achieved in over 50% of
patients with high grade NHL (Fisher et al., 1983; Connors
& Klimo, 1988; Coleman et al., 1988). However, these
patients comprise a heterogenous group with varied patterns
of disease and differing clinical outcome. The problems
associated with the histological classification of NHL are well
recognised (NCI Non-Hodgkin's Lymphoma Classification
Project Writing Committee, 1985), and reproducible quan-
titative methods of tumour classification are required to con-
fer additional prognostic information to guide the clinician in
the selection of the most appropriate therapeutic approach.
FCM analysis represents a method for the rapid estimation
of nuclear DNA content in tumour cell populations, pro-
viding information on the potentially important tumour
parameters of DNA ploidy and proliferative activity.
Previous FCM studies in NHL have suggested that both
tumour cell proliferation and the incidence of DNA aneup-
loidy increase with progression from low to high grade his-
tology (Scarffe & Crowther, 1981; Braylan et al., 1984;
Srigley et al., 1985; Christensson et al., 1986; Morgan et al.,
1986; Bauer et al., 1986; Juneja et al., 1986), and correspon-
dingly, aneuploid tumours and highly proliferative tumours
have been shown to run a more aggressive clinical course.
The reported incidence of aneuploidy in high grade lym-
phoma varies considerably between studies while published
data on PI and S phase % show greater concordance; most
series demonstrate a wide range of proliferative activity in
tumours of high grade histology. Published studies, however,
have failed to show conclusively whether within the category
of high and intermediate grade NHL the presence of DNA
aneuploidy and the variations in proliferative activity have
prognostic significance.
In an attempt to answer these questions we have per-
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formed FCM analysis on a large group of patients receiving
uniform treatment in one centre, to establish the clinico
pathological correlations and the prognostic significance of
DNA aneuploidy and proliferative activity in high and
intermediate grade NHL.
Materials and methods
Patient details
Pre-treatment paraffin embedded biopsy material was
obtained from 225 patients treated in protocols for high
grade lymphoma by the Manchester Lymphoma Group
between 1975 and 1986. All patients had high or intermediate
grade histology at presentation, and none had received prior
chemotherapy or radiotherapy. Twenty-eight cases were not
suitable for analysis due to inadequate amount of tissue (8
cases), low grade histology on review (11 cases) or uninter-
pretable DNA histograms (9 cases). The patient details are
shown in Table I, and the details of the treatment schedules
have been outlined elsewhere (Steward et al., 1984; Wagstaff
et al., 1987). In brief, 168 patients received initial
chemotherapy using a weekly schedule of chemotherapy with
VAP (vincristine, adriamycin, prednisolone). The remaining
Table I Patient details
No. %
Age range 15-75 (median 51 years)
Clinical stage
Stage I 21 11
Stage II 43 22
Stage III 32 16
Stage IV 101 51
Bulk disease 113 57
B symptoms 84 43
Bone marrow involvement 51 26
Liver involvement 45 23
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Table II Histological classification
Kiel Rappaport
No. % No. %
Intermediate
Centroblastic-centrocytic f+ d 13 7 Diffuse histiocytic 85 43
Centrocytic (small and large cell) 25 13 DPDL 79 40
Centroblastic-centrocytic, d 11 6 Diffuse mixed 17 9
High grade Others 16 8
Centroblastic 41 21
Lymphoblastic (including Burkitt) 23 12
Immunoblastic 32 16
High grade unclassified 34 16
'Histiocytic' 12 6
Not available in Kiel 6 3
Total 197 100 197 100
f, follicular; d, diffuse; DPDL, diffuse poorly differentiated lymphocytic.
patients with localised disease received initial radiotherapy
and were subsequently randomised to receive either adjuvant
VAP or a three-weekly cycling regimen of CMOPP (cyc-
lophosphamide, vincristine, procarbazine and prednisolone).
In all cases the histology was reviewed by one of the
authors (M.H.) and classified using the Rappaport
classification and a modified Kiel system incorporating an
intermediate grade (Nabholtz et al., 1987) (Table II). The 12
cases described as 'histiocytic' include nine with primary
gastrointestinal involvement, initially diagnosed as 'malignant
histiocytosis of the intestine'; many of these cases are now
being recognised as T cell in origin (Isaacson et al., 1985). In
addition, the diffuse unclassified category includes some cases
of probable T cell lymphoma, but data from immunopheno-
typing are not available in the majority of these cases.
Flow cytometric analysis
Thin (4tm) sections were cut from each paraffin block and
stained with Haematoxylin and Eosin to confirm the his-
tological classification of the tumour and to ensure adequate
tumour representation in the section. Paraffin blocks were
only included in the study if more than 25% of the tissue
section contained tumour. Adjacent 30iLm sections were then
cut from each block for FCM analysis. Where possible more
than one representative block was analysed from the same
tumour (total 305 paraffin blocks from 197 patients) to assess
intra-tumour variation in DNA content. The isolation of
nuclei was performed by the method of Hedley et al. (1983),
and the resulting nuclear suspension was stained with 4',
6'-diamidino-2-phenylindole-dihydrochloride DAPI (Sigma)
in RPMI 1640 culture medium, pH 7.4 at room temperature
for 30 min; it was filtered through 35 yim nylon gauze before
analysis. FCM analysis was performed using an EPICS V
flow cytometer (Coulter Electronics, FL, USA), with a
Spectre Physics 20-20 argon ion laser operating at 150 mW
ultra-violet, with an excitation wavelength of 357 nm and an
emission fluorescence measured at 408 nm. The coefficient of
variation (CV) for the GO/GI peak was calculated using the
standard EPICS 'STATS' computer software. The values of
CV for the diploid tumours ranged from 4.2 to 9.8, (median
6.2), for the aneuploid tumours from 4.9 to 9.0 (median 6.1),
and for the near diploid tumours from 8 to 13 (median 11).
Before sample analysis the machine was calibrated using a
suspension of reference human lymphocytes stained with
DAPI. The ratio of the GO/GI peak of the tumour sample to
the GO/GI peak of the reference cells was defined as the
relative fluorescence. A minimum of 30,000 nuclei were
analysed from each sample.
Ploidy estimation
Tumours were defined as diploid by the presence of a single
symmetrical GO/GI peak (Figure la). In a number of tumours
a single broad asymmetrical GO/G1 peak (CV ) 10) was
obtained which persisted despite repeat analyses. This
phenomenon was not found in 60 analyses on paraffin
embedded material from non-malignant 'reactive' lymph
nodes (results not shown), suggesting that this may result
from a minor degree of aneuploidy. We therefore considered
it appropriate to define these tumours as near diploid (Figure
lb). Tumours with more than one discrete GO/GI peak were
considered aneuploid (Hiddeman et al., 1984) (Figure Ic), and
the degree of aneuploidy was expressed as a DNA index (DI)
which was defined as the ratio of the channel position of the
GO/GI aneuploid peak to the channel position of the GO/GI of
the diploid peak. Tetraploid tumours comprised an aneuploid
peak containing >10% of cells (DI 1.9-2.1) with a discrete
identifiable S and G2M (Figure Id).
Measurement ofproliferative activity
Proliferative activity was estimated in terms of S phase %
and proliferative index (PI). PI represented the sum of cells
in S and G2M expressed as a percentage of the total cell
number. The percentage of cells in each cell cycle compart-
ment (GO/GI, S phase and G2M) were estimated using a
manual technique formulated in this institute. In brief, cur-
sors were placed symmetrically on either side of the GO/GI
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Figure 1 Description of four ploidy categories: a, diploid,
b near diploid; c, aneuploid; d, tetraploid.
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peak by two operators working independently. The
coefficient of variation for the GO/GI was calculated using the
'STATS' computer program (Coulter Electronics, FL, USA)
and the number of cells lying within the GO/GI peak was
recorded. This procedure was repeated for the S phase com-
partment and G2M.
An estimate of proliferative activity was made in all dip-
loid tumours and in 60% of non-diploid tumours. The
significance of proliferative activity was assessed with and
without the non-diploid tumours.
In a preliminary study (unpublished data) the data on
proliferative activity derived from the 'manual' technique
described was compared with data obtained from the stan-
dard computer algorithm available in this institute. We found
significantly greater uniformity of results from the manual
technique as compared with the computer method, and thus
the manual technique was adopted for this series of patients.
Table HI Cases showing ploidy variation on 207 analyses from
different regions of 81 tumours
No. twnours Percentage
Change in ploidy showing discrepancy (of81 cases)
Near diploid/diploid 7 9
Near diploid/aneuploid 3 3.5
Diploid/aneuploid 3 3.5
Total 13 16
significantly associated with histological subtype in the Kiel
classification (P = 0.002). The median relative fluorescence of
the centrocytic lymphomas was 40 compared with 76 for the
centroblastic tumours. An association was observed between
the CV of the GO/GI peak and histological subtype (Kiel); the
median CV for the centrocytic tumours was 7.0 compared
with a median of 5.4 for the lymphoblastic tumours, but this
association did not reach statistical significance (P = 0.08).
Statistical analysis
The prognostic influence of DNA content was estimated in
terms of attainment of CR, overall survival, relapse-free sur-
vival (RFS) and survival following the attainment of CR by
plotting Kaplan-Meier survival curves (Kaplan & Meier,
1958). These curves were then compared using the log rank
test (Peto & Peto, 1972). Survival was calculated from the
start of treatment to the last follow-up or death. RFS was
defined as the interval between the confirmed establishment
of CR and the date of documented relapse. The
clinicopathological correlations of ploidy and PI were
examined using X2 and non-parametric tests.
The DNA data was included in a Cox multivariate analysis
(Cox, 1972) with other known prognostic factors to establish
the factors independently associated with survival, and a
stepwise logistic regression procedure was performed to
determine combinations of patient characteristics and disease
parameters important in predicting CR.
Results
The 5-year survival rate for the 197 patients was 50%, with a
median follow-up of 72 months (range 19-135 months).
Clinicopathological correlations
Ploidy Fifty-one per cent of tumours were diploid, 28%
were true aneuploid, 14% near diploid and 7% tetraploid. In
81 cases adequate tissue was available to permit repeat FCM
analyses from different sites within the tumour, allowing a
total of 207 analyses to be performed on 81 tumours. Varia-
tion in ploidy status was observed in 13/81 tumours (16%)
(Table III). Ten of the 13 cases involved near diploid
tumours and in only 3/81 (4%) was there a clear ploidy
discrepancy with diploid and aneuploid DNA stem lines
coexisting within the same tumour. In the aneuploid and
tetraploid tumours the percentage of cells in the aneuploid
peak was noted to vary in different regions of the tumour,
but the DNA index remained constant. Sixteen tumours were
extranodal (gastrointestinal tract 9, skin 4, thyroid 2, testis
1), and nine of these were diploid, three near diploid, four
aneuploid.
There was no significant association between ploidy status
and histological subtype in the Rappaport or Kiel
classifications. DNA ploidy was not significantly associated
with patient age, Ann Arbor stage, bulk disease, bone mar-
row involvement, constitutional symptoms, site of disease at
presentation or the site of subsequent relapse. In the aneup-
loid and tetraploid tumours, the percentage of cells in the
aneuploid peak varied from 6 to 75%. The mean percentage
of cells in the aneuploid peak was greater in those tumours
associated with bone marrow involvement (50%) compared
with the rest (35%) (P = 0.03). There was considerable varia-
tion in relative fluorescence between diploid tumours (chan-
nel 15-149, median 62), and relative fluorescence was
Proliferative activity The value for proliferative index varied
between tumours from 2 to 51% (median 14%), and S phase
% ranged from 0.5 to 32% (median 9%). The intra-tumour
variation in PI estimated from multiple analyses involving 72
tumours revealed a variation of within ± 5% (standard
deviation of the error for PI = 4.9%). There was no
significance difference in proliferative activity between the
tumour samples obtained from extranodal sites and those
derived from nodal tissue.
PI correlated with histological subtype in the Kiel
classification (P = 0.001), but not in Rappaport (P = 0.28).
The lymphoblastic tumours showed the highest proliferative
activity (median PI 20%), while the lowest proliferative
activity was seen in the centrocytic lymphomas (median PI
10%) (Figure 2). Using the modified Kiel system (Nabholtz
et al., 1987), the median PI for the 'intermediate' grade
tumours was 9% compared with 17% for the high grade
tumours (P <0.001). A similar pattern was seen for the S
phase %, and for both PI and S phase % when the analysis
was restricted to diploid tumours alone. Patients presenting
with liver infiltration showed a significantly higher tumour PI
(median 18%) than those without liver involvement (median
12%) (P = 0.02), and tumours primarily involving the gast-
rointestinal tract were also associated with an elevated PI,
but this did not reach statistical significance. However, PI
was not significantly associated with patient age, Ann Arbor
stage, bulk disease, bone marrow involvement, constitutional
symptoms or the site of subsequent relapse.
DNA content andprognosis
Ploidy DNA ploidy was not significantly associated with
response rate, overall survival (Figure 3), RFS or survival
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Figure 2 The association between histological classification
(Kiel) and proliferative index (PI). CC, centrocytic; DU diffuse
high grade unclassified; CB, centroblastic; IB immunoblastic; LB,
lymphoblastic.
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with a high PI (>20). Histological classification (Kiel and
Rappaport) did not correlate with response, and an analysis
of response rates within separate histological categories
revealed that the association of PI with response was most
marked in the centroblastic tumours; the median PI for the
centroblastics entering CR was 12% compared with 22% for
the partial and non-responders (P = 0.013). In an analysis of
all patients, PI did not significantly correlate with overall
survival, RFS nor survival following CR. The analysis was
repeated restricting the estimation of proliferative activity to
diploid tumours only. This revealed a decrease in median
survival with increasing PI: tumours with PI values >10%
(39 patients), 10-19% (37 patients) and <19% (24 patients)
showed median survivals of 66, 45 and 16 months respec-
tively, but this did not reach statistical significance. A sur-
vival advantage associated with a low PI was also apparent
in the centroblastic tumours, but again this was not statis-
tically significant.
DNA content on relapse The histological classification ofthe
20 tumours on relapse remained unchanged. However, a
comparison of tumour DNA content in the initial biopsy and
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status in 13/20 cases, yet these ploidy transitions followed no
Months clear pattern (Table IV). An increase in PI was observed in Figure 3 Overall survival of 197 patients broken down by ploidy the biopsies at relapse in 14/20 cases, PI remained unchanged
category. in two cases and showed a decrease in four cases. A com-
parison of the changes in PI within each patient showed that
following CR. Similarly, when the patient population was the rise in PI on relapse was statistically significant
subdivided by histological category (Kiel and Rappaport) (P = 0.017) (Figure 4).
and reanalysed, ploidy status did not prove a significant The DNA data were combined with over 20 clinical,
prognostic factor within any of the histological groups. In radiological and laboratory disease parameters and subjected
the patients with aneuploid tumours the DNA index did not to a Cox's multivariate analysis for independent association
correlate with prognosis. with survival. None of the FCM parameters independently
predicted for survival, and the results of this detailed prog-
Proliferative activity The median PI for patients achieving nostic factor analysis have been published elsewhere (Cowan
CR was 12% as compared with 16% for the remaining et al., 1989). Treatment schedule was not significantly
patients (P = 0.023). Seventy-one per cent of patients with a associated with clinical outcome.
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Figure 4 Variation in proliferation index PI between initial biopsy and site of subsequent relapse in 20 patients. 1U, primary; *,
relapse.
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Table IV Variation in ploidy in 20 tumours on relapse
First biopsy Ploidy change
9 Diploid 5 unchanged
2 to aneuploid
2 to tetraploid
2 Near diploid 2 to diploid
7 Aneuploid 2 unchanged
4 to diploid
1 to near diploid
2 tetraploid 2 to aneuploid
Discussion
In this study we have assessed the clinicopathological correla-
tions and the prognostic relevance of DNA content in a large
group of patients subjected to uniform pre-treatment evalua-
tion and treated using equivalent therapeutic schedules.
Previous prospective studies of DNA content in NHL using
fresh material have been limited by small patient numbers
and short follow-up, and in the retrospective studies reported
patients have seldom received standard therapy and the
association of DNA content with clinical outcome has not
been considered in the context of other important prognostic
parameters.
Ploidy
The incidence of non-diploid DNA content in this group of
patients was 49%. Reported aneuploidy rates in high and
intermediate grade NHL have varied between 31% and 65%
(Christensson et al., 1986; Morgan et al., 1986; Bauer et al.,
1986; Juneja et al., 1986), and Diamond et al. (1982) reported
an 80% incidence of aneuploidy in high grade NHL,
although this variation may in part be attributed to different
criteria employed in the definition of aneuploidy. When inter-
preting ploidy data it is important to establish the degree of
intra-tumour ploidy variation. In this study, DNA ploidy
was assessed in representative tissue from different regions of
81 tumours, and in only 4% of cases was there unequivocal
intra-tumour DNA stem line heterogeneity. In 10 cases
(11%) the ploidy discrepancy observed involved near diploid
tumours which (as discussed below) represent a category in
which the authors acknowledge an inability to distinguish
with any certainty between diploid and aneuploid, and thus
we must accept that some of these cases of ploidy variation
may be artefactual rather than real. Interestingly, among the
aneuploid tumours the ratio of aneuploid to diploid cells
varied in different regions of the tumour, although the DNA
index remained constant.
The values of CV in this study were higher than those we
obtained using fresh tissue (unpublished data). This apparent
disadvantage of the technique using paraffin embedded tissue
has been reported by some groups (Bauer et al., 1986;
McIntire et al., 1987), but not by others (Camplejohn &
Macartney, 1985), and raises the possibility that the larger
values of CV may mask minor degrees of aneuploidy. How-
ever, a comparative study of flow cytometric DNA analysis
using fresh tissue (median CV = 3.1) and paraffin embedded
tissue (median CV = 6.1) showed consistent identification of
ploidy status in 33/35 tumours. In 23 of these cases karyotyp-
ing was also performed, and a comparison of FCM ploidy
analysis and karyotyping revealed good agreement in 20/23
cases (unpublished data). Interestingly, although a high CV is
usually attributed to technical factors, in this study the value
of CV was observed to vary with histological subtype,
although this association did not reach statistical significance,
possibly as a result of the small patient numbers. This
phenomenon may represent an increased incidence of
fminimal' aneuploidy in the histological categories with larger
CVs (e.g. centrocytic tumours), or alternatively it may reflect
differences in the uniformity of the DNA binding of DAPI in
different histological subtypes. In 14% of tumours a per-
sistently broad asymmetrical GO/GI peak was observed.
Although this could represent technical artefact, the re-
producibility of the pattern, combined with the apparent
absence of this phenomenon in 60 similar analyses performed
on benign 'reactive' nodes, implied that a minor degree of
DNA aneuploidy may be present, and therefore we felt that
these tumours deserved inclusion in the overall analysis in a
discrete category designated 'near diploid'. However, the
clinical behaviour of these near diploid tumours did not
significantly differ from tumours in the other ploidy
categories, and a re-analysis of the data excluding the near
diploid category revealed an identical outcome.
By using an internal standard of fixed lymphocytes we
were able to make an estimate of the relative fluorescence of
the GO/GI peak of the diploid tumours. In common with
other groups (Hedley et al., 1983; Bauer et al., 1986; Schutte
et al., 1985), this was found to vary considerably, a
phenomenon which has been attributed to technical factors
related to methods of fixation, and one which has precluded
the use of an internal standard for the FCM estimation of
ploidy in nuclei derived from paraffin embedded tissue. How-
ever, interestingly, we have found a significant association
between relative fluorescence and histology in Kiel, sugges-
ting that there may be a difference in uptake and binding of
the DNA stain by different histological subtypes.
We failed to show a significant association between ploidy
status and histological subtype in Rappaport or Kiel, and
within this modified Kiel system there was no difference in
aneuploidy rates between intermediate and high grade
tumours; other groups (Christensson et al., 1986; Srigley et
al., 1985), examining the association of ploidy with histology
in the Working Formulation, have also reported similar
aneuploidy rates in intermediate and high grade tumours. In
this study we have made a detailed examination of the
association between ploidy and other important disease
parameters, and have found no significant relationship
between ploidy and Ann Arbor stage, B symptoms, site of
disease at presentation or site of subsequent relapse. Bauer et
al. (1986) reported an increased incidence of bone marrow
involvement in patients with aneuploid tumours and,
although our results failed to confirm this finding, we did
note that in the aneuploid tumours the percentage of cells in
the aneuploid peak was significantly greater in the patients
with bone marrow involvement compared the rest
(P = 0.015).
Ploidy did not correlate with response to treatment in our
study, and few other investigators have examined this
association. Morgan et al. (1986) suggested that aneuploidy
correlated with an improved response rate, yet this was based
on a relatively small number of patients (the CR rate in six
patients with aneuploid tumours was higher than in 17
patients with diploid tumours). Similarly, we were unable to
show a significant association between ploidy and RFS or
overall survival, and despite several reports suggesting that
the incidence of aneuploidy increases with progression from
low to high grade, most studies have failed to show any
correlation between aneuploidy and prognosis among
tumours of similar grade. Woolidge et al. (1988), studying 52
patients with diffuse large cell lymphoma, reported an im-
proved 2-year survival in aneuploid tumours, whereas Leh-
tinen et al. (1989), in a series of 117 patients with
unfavourable histology, found an improved survival in a
subgroup of patients with diploid tumours. Our findings
would indicate that the presence of aneuploid cells within
tumours does not influence the biological behaviour of the
tumour, and these cells merely represent non-viable by-
products of disordered neoplastic cell division. The 'aneu-
ploid cell' identified using standard FCM analysis constitutes
a cell with abnormal total nuclear DNA content, while the
more subtle rearrangements and deletions of genetic material,
which clearly do influence tumour behaviour, are not discer-
nible using this technique.
Proliferative index (PI)
We have shown a marked variation in proliferative activity in
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findings have been reported by other groups (Christensson et
al., 1986; Srigley et al., 1985; Morgan et al., 1986; Bauer et
al., 1986; Juneja et al., 1986). This might have been explained
by sampling error due to marked intra-tumour variation in
PI, but we have found relatively little proliferative
heterogeneity within tumours. Further, we have shown a
significant association of PI with histological subtype. In the
modified Kiel system, the median PI in the high grade
tumours was significantly greater than for those of
intermediate grade, and similar results have been reported by
other groups using the Working Formulation (Srigley et al.,
1985; Christensson et al., 1986). The lack of an association
between PI and the Rappaport classification in this study
contrasts with the findings of Christensson et al. (1986), who
reported a significantly higher S phase % in the diffuse
histiocytic tumours compared with the DPDL and the diffuse
mixed categories. Bauer et al. (1986), have reported an
association between a high PI and the presence of extranodal
disease, while in our study only liver involvement was
significantly associated with increased proliferative activity,
and although gastrointestinal tumours also appeared to show
higher proliferative activity, this did not reach statistical
significance.
We have shown that in this group of patients an elevated
value for PI predicts for a poor response to therapy (49% vs
71%), and this association was most marked in the centro-
blastic tumours. Data from other studies addressing this
important question are conflicting; Srigley et al. (1985) noted
an increased response rate in tumours with the larger
proliferative indices, a finding explained in the context of the
increased sensitivity of cycling cells to ionising radiation and
cytotoxic drugs. Other studies, however, have reported
similar results to ours (Bauer et al., 1986; Woolidge et al.,
1988), and alternative factors associated with high prolife-
rative rates may play an important part in tumour response;
these include neoplastic cell repopulation between courses of
chemotherapy or between fractions of radiotherapy, and the
increased probability the emergence of 'resistant' clones in
highly proliferative tumours. Thus, we may infer from our
data that the patients with highly proliferative tumours
(PI>20%) would be candidates for more intensive induction
chemotherapy.
Despite the association between PI and attainment of CR
in our patients, neither PI nor S phase % significantly
predicted for survival. Few groups have assessed the prog-
nostic relevance of proliferative activity within high grade
and intermediate grade NHL (Bauer et al., 1986; Young et
al., 1987; Woolidge et al., 1988; Lehtinen et al., 1989). The
Chicago group (Bauer et al., 1986), reporting their results on
50 patients with diffuse large cell lymphoma, demonstrated a
significantly improved survival in 33 patients with a low PI
(<20%) compared with six patients with a high PI (>20%).
Interestingly, in their series no correlation was found between
proliferative activity and mitotic count. Young et al. (1987),
in their study of 111 patients with high and intermediate
grade NHL, showed that among the diploid diffuse large cell
tumours a significantly better survival was seen in 22 patients
with S phase < 19% compared to nine patients with an S
phase >19%. Woolidge et al. (1988) also showed an im-
proved survival in patients with low proliferative activity, but
it is noteworthy that in all three studies (Bauer et al., 1986;
Young et al., 1987; Woolidge et al., 1988) the prognostic
assessment was made on relatively short follow-up period.
Lehtinen et al. (1989), on the other hand, reporting on
patients with longer follow-up, found no significant associ-
ation between proliferative activity and prognosis. Although
our results in the diploid tumours did show a trend towards
a survival advantage in those tumours with low proliferative
activity, this did not reach statistical significance. These
apparent discrepancies may be explained by the effect of
differing treatment protocols, differing patient characteristics
and duration of follow-up, or variations in methods for the
estimation of proliferative activity.
DNA content on relapse
There have been no published reports describing the changes
in DNA content in high and intermediate grade lymphomas
between tumour at presentation and relapse. Macartney et al.
(1986) studied second biopsies in 22 patients with low grade
lymphoma, and found that the mean S phase % was higher
at relapse, although this did not reach statistical significance.
However, they also showed that the mean S phase % in the
initial biopsy was significantly higher in the 11 patients who
transformed to high grade histology compared with the
remaining 11 patients whose histology was unchanged at
relapse. In our study, despite similar histological appearance
at relapse, ploidy status differed in 13/20 cases. This variation
between primary tumour and recurrence contrasts with the
relative stability of ploidy observed in different regions within
the same tumour. We also demonstrated a significant in-
crease in PI in the biopsy tissue at relapse compared with the
initial biopsy at presentation. The altered DNA content in
many tumours at relapse may represent the selection of
resistant clones within the tumour, and this may be impor-
tant in explaining the relative resistance of relapsed high
grade NHL to salvage therapy.
Conclusions
The aim of this study was to assess the significance of DNA
content derived from a simple technique which would be
appropriate for incorporation into clinical practice. We
recognise that this represents a relatively crude method for
the estimation of ploidy in tumour cell populations, and the
values for proliferative activity are prone to a degree of
inaccuracy depending on the relative number of admixed
non-neoplastic cells and the method of data analysis, partic-
ularly in the non-diploid cases. However, using this technique
in a large group of patients with intermediate and high grade
NHL, we have demonstrated a relative uniformity of ploidy
status in different regions of the tumour; a feature which
contrasts with the marked variation observed between
primary tumour and tumour at relapse. Similarly, pro-
liferative activity showed little intra-tumour variation, yet
was significantly increased in tumours at the site of relapse.
However, ploidy and PI did not prove significant predictors
of survival when included in multivariate analysis with other
known prognostic factors. Interestingly, PI correlated with
histological subtype and response to therapy, and this
parameter warrants further evaluation in future studies.
The authors wish to offer their thanks to the histopathologists in the
north-west region for their ready co-operation in providing paraffin
embedded biopsy tissue for analysis in this study, and to Michael
Hughes and Jeffrey Barry for their expert technical assistance.
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